Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Twist Bioscience Corporation

Stage 2 · Advancing · week 39

As of Oct 22, 2026, Twist Bioscience is in Stage 2, the uptrend phase, now in week 39 (since Jan 16, 2026). It closed at $135.47, 33.9% below its 52-week high and above its 200-day average, which is rising.

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. More about the company

$135.47
-9.09% today
$9.0B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is TWST early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 17w
S2 14w
S3 14w
S4 20w
S2 40w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S2 7w → S3 9w → S2 17w → S3 7w → S2 14w → S3 14w → S2 13w → S3 1w → S4 20w → S1 3w → S4 10w → S1 11w → S2 40w current
Total tracked: 165 weeks across 14 stage runs.

TWST among Biotechnology5th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
vs 52W High
-33.9%
$25.45 lo$205.00 hi
33.9% below 52W high, far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 39
1w13w26w
Week 39, mature
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
58.6%
200 DMA: $85.42 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
1.14x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-14.5%
3M
+50.1%
6M
+130.2%
YTD
+318.2%
1Y
+305.7%
Scan Membership
Breakout Watch
Latest: 2024-12-03
6 appearances in last 60 days. First seen: 2019-08-19.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 39 · Vol 1.14x
2026-10-21S2
Wk 39 · Vol 0.97x
2026-10-20S2
Wk 39 · Vol 0.86x
2026-10-19S2
Wk 38 · Vol 0.68x
2026-10-16S2
Wk 38 · Vol 1.22x
2026-10-15S2
Wk 38 · Vol 1.53x
2026-10-14S2
Wk 38 · Vol 0.92x
2026-10-13S2
Wk 38 · Vol 0.66x
2026-10-12S2
Wk 37 · Vol 1.15x
2026-10-09S2
Wk 37 · Vol 1.56x
2026-10-08S2
Wk 37 · Vol 1.98x
2026-10-07S2
Wk 37 · Vol 2.78x
Moving averages & range
50 DMA
$149.47
200 DMA
$85.42
52W High
$205.00
52W Low
$25.45
5D Low
$132.75
Resistance levels (recent highs)
20d High
$205.00
60d High
$205.00
120d High
$205.00
250d High
$205.00
Next resistance
+51.3%
to 20d High
ROE
-29.6%
Profit margin -31.7%
Dividend Yield
0.00%
P/B 19.0

Twist Bioscience: quick answers

What stage is Twist Bioscience in?

As of Oct 22, 2026, Twist Bioscience (TWST) is in Stage 2, the uptrend phase. It entered Stage 2 on Jan 16, 2026 and is in week 39. What the four stages mean

Is Twist Bioscience in an uptrend?

Yes. Twist Bioscience is in a Stage 2 uptrend. It trades 58.6% above its 200-day average, which is rising.

How far is Twist Bioscience from its 52-week high?

Twist Bioscience closed at $135.47 on Oct 22, 2026, 33.9% below its 52-week high of $205.00. Its 52-week low is $25.45.

How has Twist Bioscience performed over the past year?

As of Oct 22, 2026, Twist Bioscience is up 305.7% over the past year and up 318.2% so far in 2026.

Which sector and industry is Twist Bioscience in?

Twist Bioscience is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.